Liu Heqian, Wang Jiawei, Tao Lingsong, Liu Yingqing, Huang Houbao
The Fifth School of Clinical Medicine, Anhui Medical University, Hefei, Anhui, China.
Department of Urology, The Second People's Hospital of Wuhu, Wuhu, Anhui, China.
Sci Rep. 2025 Aug 9;15(1):29163. doi: 10.1038/s41598-025-14493-z.
Renal cell carcinoma (RCC) is one of the most common tumors of the urinary system. Herein, we examined the epidemiology and prognostic factors of RCC and investigated the prognosis of partial nephrectomy (PN) compared to radical nephrectomy (RN) for T1b RCC over the past 20 years. We obtained data from the Surveillance, Epidemiology, and End Results (SEER)-17(2000-2021) database for epidemiological and survival analysis. The age-adjusted incidence of RCC per 100,000 persons significantly increased from 9.3 to 13.2 (annual percent change [APC]: 1.3%, 95% CI: 1.0-1.7). The mortality also increased from 0.8 to 4.3 (APC: 4.1%, 95% CI: 3.2-5.0). The incidence of RCC patients who underwent PN significantly increased from 0.9 to 4.7(APC:6.4%, 95% CI:4.9-7.9). Moreover, mortality for patients who underwent PN increased from 0 to 0.3% (APC: 13.0%, 95% CI: 11.4-14.6%), while mortality for those who underwent RN increased from 0.3 to 2.3% (APC: 3.6%, 95% CI: 2.2-5.0%). The multivariate Cox model indicated that PN was an independent predictor of good prognosis for both ACM and CSM, before and after propensity score matching. In addition, Kaplan-Meier survival curves showed that the RN group had a higher risk of both ACM and CSM. In the present study, we demonstrated that both the incidence and mortality of RCC have increased over the past 20 years. The number of RCC patients undergoing PN has also risen significantly in recent years. Our findings indicate that PN confers a survival benefit compared to RN.
肾细胞癌(RCC)是泌尿系统最常见的肿瘤之一。在此,我们研究了RCC的流行病学和预后因素,并调查了过去20年中T1b期RCC行部分肾切除术(PN)与根治性肾切除术(RN)相比的预后情况。我们从监测、流行病学和最终结果(SEER)-17(2000 - 2021)数据库获取数据进行流行病学和生存分析。每10万人中经年龄调整的RCC发病率从9.3显著增至13.2(年变化百分比[APC]:1.3%,95%置信区间:1.0 - 1.7)。死亡率也从0.8增至4.3(APC:4.1%,95%置信区间:3.2 - 5.0)。接受PN的RCC患者发病率从0.9显著增至4.7(APC:6.4%,95%置信区间:4.9 - 7.9)。此外,接受PN患者的死亡率从0增至0.3%(APC:13.0%,95%置信区间:11.4 - 14.6%),而接受RN患者的死亡率从0.3%增至2.3%(APC:3.6%,95%置信区间:2.2 - 5.0)。多变量Cox模型表明,在倾向评分匹配前后,PN都是总累积死亡率(ACM)和癌症特异性死亡率(CSM)良好预后的独立预测因素。此外,Kaplan - Meier生存曲线显示,RN组的ACM和CSM风险更高。在本研究中,我们证明了在过去20年中RCC的发病率和死亡率均有所增加。近年来接受PN的RCC患者数量也显著上升。我们的研究结果表明,与RN相比,PN具有生存获益。